Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Study of Efficacy, Safety, and Withdrawal and Retreatment With Brodalumab (AMG 827) in Moderate to Severe Plaque Psoriasis Subjects (AMAGINE-1)

This study has been terminated.
(Sponsor decision)
Information provided by (Responsible Party):
Amgen Identifier:
First received: September 10, 2012
Last updated: August 6, 2015
Last verified: August 2015
No Study Results Posted on for this Study
  Study Status: This study has been terminated.
  Estimated Study Completion Date: August 2015
  Primary Completion Date: May 2014 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: April 1, 2015